261P - Breast cancer subtypes and outcome in elderly breast cancer patients aged 70 years and older

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Breast Cancer, Early Stage
Geriatric Oncology
Presenter Robert Königsberg
Authors R. Königsberg1, G. Pfeiler2, N. Hammerschmid2, T. Klement2, A. Brunner3, C. Dittrich1
  • 1Ludwig Boltzmann Institute For Applied Cancer Research (lbi-acr Vienna) – Lb Cluster Translational Oncology, 3rd Medical Department – Centre For Oncology And Haematology, Kaiser Franz Josef-Spital, 1100 - Vienna/AT
  • 2Department Of Obstetrics And Gynaecology, Medical University of Vienna, 1090 - Vienna/AT
  • 3Department Of Obstetrics And Gynaecology, Landesklinikum Thermenregion Moedling, 2340 - Mödling/AT



Tumor characteristics and patterns of recurrence in luminal A, luminal B, Her2 pos and triple negative breast cancer (bc) patients (pts) 70 years and older are still an area of uncertainty. In this investigation clinical pathological characteristics, disease recurrence and death were analysed according to the 4 bc subcategories and age in pts ≥70 years.


Data of 274 elderly bc pts (≥70 years of age) diagnosed between 1998 and 2004 were retrospectively analyzed by computer based chart information. Baseline tumor characteristics, patient demographics and patterns of recurrence were compared between luminal A, luminal B, Her2 pos and triple negative bc pts and 3 age categories (70-75, 76 -80, ≥ 81 years).


Mean age was 76.95 years and mean time of follow-up was 52.23 months (range 0-144 months). Overall, recurrences were detected in 18.4% of pts. At the end of follow-up 69.0% of pts were alive, 15.0% and 16.1% died from bc and from other causes, respectively (p = 0.745). Median overall survival (OS) was 114.1 months (95% confidence interval 100.3 -181.7 months). 41.1%, 20.4%, 16.1% and 12.5% of patients had luminal A, luminal B, Her2 pos and triple negative bc, respectively. No significant differences were found regarding recurrences according to bc subtypes (p = 0.241). Triple negative bc had a significant shorter OS compared to lumianl A, luminal B and Her2 pos bc (72.7 months vs 124.1, 119.4 and 105.0 months, respectively (p < 0.001)). Overall, 21.5% of pts received no therapy. Pts aged ≥81 years (15.8%) received significantly less (p < 0.01) chemo-/antihormonal therapy compared to pts ≤80 years. Pts aged 70-75 years (42.7%) had significantly (p = 0.032) more recurrences compared to pts 76 years or older. Pts aged 70 - 75, 76 - 80 and ≥ 81 years had median OS of 116.9, 115.4 and 73.1 months.


Pts aged 70-75 years had significantly more recurrences; perhaps due to their lower risk of death from other causes. These data emphasize the necessity to foresee all bc subgroups of the elderly for adjuvant treatment irrespective of age but carefully considering co-morbidities, performance status and life-expectancy.


All authors have declared no conflicts of interest.